Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 2
1991 2
1992 4
1993 4
1994 4
1995 4
1996 4
1997 2
1998 4
1999 3
2000 3
2001 5
2002 6
2003 7
2004 5
2005 5
2006 3
2007 6
2008 7
2009 4
2010 10
2011 8
2012 9
2013 6
2014 15
2015 12
2016 15
2017 18
2018 23
2019 9
2020 12
2021 6
2022 6
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

215 results

Results by year

Filters applied: . Clear all
Page 1
Neuroblastoma.
Chung C, Boterberg T, Lucas J, Panoff J, Valteau-Couanet D, Hero B, Bagatell R, Hill-Kayser CE. Chung C, et al. Among authors: valteau couanet d. Pediatr Blood Cancer. 2021 May;68 Suppl 2(Suppl 2):e28473. doi: 10.1002/pbc.28473. Pediatr Blood Cancer. 2021. PMID: 33818884 Free PMC article. Review.
Advances in Risk Classification and Treatment Strategies for Neuroblastoma.
Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR, Valteau-Couanet D, Pearson AD, Cohn SL. Pinto NR, et al. Among authors: valteau couanet d. J Clin Oncol. 2015 Sep 20;33(27):3008-17. doi: 10.1200/JCO.2014.59.4648. Epub 2015 Aug 24. J Clin Oncol. 2015. PMID: 26304901 Free PMC article. Review.
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.
Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, London WB, Seibel NL, Lindwasser OW, Maris JM, Brock P, Schleiermacher G, Ladenstein R, Matthay KK, Valteau-Couanet D. Park JR, et al. Among authors: valteau couanet d. J Clin Oncol. 2017 Aug 1;35(22):2580-2587. doi: 10.1200/JCO.2016.72.0177. Epub 2017 May 4. J Clin Oncol. 2017. PMID: 28471719 Free PMC article. Review.
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I, Laureys G, Brock P, Michon JM, Owens C, Trahair T, Chan GCF, Ruud E, Schroeder H, Beck Popovic M, Schreier G, Loibner H, Ambros P, Holmes K, Castellani MR, Gaze MN, Garaventa A, Pearson ADJ, Lode HN. Ladenstein R, et al. Among authors: valteau couanet d. Lancet Oncol. 2018 Dec;19(12):1617-1629. doi: 10.1016/S1470-2045(18)30578-3. Epub 2018 Nov 12. Lancet Oncol. 2018. PMID: 30442501 Clinical Trial.
The challenge of defining "ultra-high-risk" neuroblastoma.
Morgenstern DA, Bagatell R, Cohn SL, Hogarty MD, Maris JM, Moreno L, Park JR, Pearson AD, Schleiermacher G, Valteau-Couanet D, London WB, Irwin MS. Morgenstern DA, et al. Among authors: valteau couanet d. Pediatr Blood Cancer. 2019 Apr;66(4):e27556. doi: 10.1002/pbc.27556. Epub 2018 Nov 26. Pediatr Blood Cancer. 2019. PMID: 30479064 Review.
Medulloblastoma in young children.
Rutkowski S, Cohen B, Finlay J, Luksch R, Ridola V, Valteau-Couanet D, Hara J, Garre ML, Grill J. Rutkowski S, et al. Among authors: valteau couanet d. Pediatr Blood Cancer. 2010 Apr;54(4):635-7. doi: 10.1002/pbc.22372. Pediatr Blood Cancer. 2010. PMID: 20146217 Review.
Reply to K. Beiske et al.
Sokol E, Desai AV, Applebaum MA, Valteau-Couanet D, Park JR, Pearson ADJ, Schleiermacher G, Irwin MS, Hogarty M, Naranjo A, Volchenboum S, Cohn SL, London WB. Sokol E, et al. Among authors: valteau couanet d. J Clin Oncol. 2020 Nov 1;38(31):3720-3721. doi: 10.1200/JCO.20.02147. Epub 2020 Sep 15. J Clin Oncol. 2020. PMID: 32931402 No abstract available.
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.
Moreno L, Weston R, Owens C, Valteau-Couanet D, Gambart M, Castel V, Zwaan CM, Nysom K, Gerber N, Castellano A, Laureys G, Ladenstein R, Rössler J, Makin G, Murphy D, Morland B, Vaidya S, Thebaud E, van Eijkelenburg N, Tweddle DA, Barone G, Tandonnet J, Corradini N, Chastagner P, Paillard C, Bautista FJ, Gallego Melcon S, De Wilde B, Marshall L, Gray J, Burchill SA, Schleiermacher G, Chesler L, Peet A, Leach MO, McHugh K, Hayes R, Jerome N, Caron H, Laidler J, Fenwick N, Holt G, Moroz V, Kearns P, Gates S, Pearson ADJ, Wheatley K; Innovative Therapies for Children with Cancer (ITCC) and European Association for Neuroblastoma Research (SIOPEN). Moreno L, et al. Among authors: valteau couanet d. J Clin Oncol. 2024 Apr 1;42(10):1135-1145. doi: 10.1200/JCO.23.00458. Epub 2024 Jan 8. J Clin Oncol. 2024. PMID: 38190578 Free article. Clinical Trial.
215 results